FLC
BBOT

Fifth Lane Capital’s BridgeBio Oncology BBOT Stock Holding History

Fifth Lane Capital’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,500
Closed -$112K – 118
2025
Q2 		$112K Buy
+10,500
New +$113K 0.14% 52

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Fifth Lane Capital's BBOT Position: Q3 2025 in Review

Fifth Lane Capital sold out of BridgeBio Oncology (BBOT) in Q3 2025, closing a stake of 10,500 shares — an estimated $112K sold.

Fifth Lane Capital first reported a position in BBOT in Q2 2025 and held it in 1 quarter. The position peaked at $112K in Q2 2025. 42 funds tracked by Wall St. Rank hold BBOT as of Q3 2025.

  • Fifth Lane Capital reported no remaining BridgeBio Oncology position as of Q3 2025 after selling out during the quarter.
  • Fifth Lane Capital sold 10,500 BridgeBio Oncology shares in Q3 2025, an estimated $112K.
  • Fifth Lane Capital first reported a position in BridgeBio Oncology in Q2 2025 and held it in 1 quarter.
  • Fifth Lane Capital's BridgeBio Oncology position peaked at $112K in Q2 2025.
  • 42 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q3 2025.

Based on Fifth Lane Capital's 13F filing for Q3 2025, filed 12 Nov 2025.